Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 3,239 | 6,886 | 2,723 | 3,537 | 4,106 |
| Gross Profit | 3,239 | 6,886 | 2,723 | 3,537 | 4,106 |
| Operating Expenses | 22,310 | 26,027 | 26,641 | 26,219 | 23,054 |
| Operating Income | -19,071 | -19,141 | -23,918 | -22,682 | -18,948 |
| Other Income | 1,059 | 1,107 | 1,002 | 845 | 284 |
| Pre-tax Income | -18,012 | -18,034 | -22,916 | -21,837 | -18,664 |
| Income Tax | 29 | 757 | 39 | 49 | -43 |
| Net Income Continuous | -18,041 | -18,791 | -22,955 | -21,886 | -18,621 |
| Net Income | $-18,041 | $-18,791 | $-22,955 | $-21,886 | $-18,621 |
| EPS Basic Total Ops | -10.37 | -10.75 | -13.25 | -12.50 | -11.00 |
| EPS Basic Continuous Ops | -10.37 | -10.87 | -13.37 | -12.73 | -10.89 |
| EPS Diluted Total Ops | -10.37 | -10.75 | -13.25 | -12.50 | -11.00 |
| EPS Diluted Continuous Ops | -10.37 | -10.87 | -13.37 | -12.73 | -10.89 |
| EBITDA(a) | $-18,390 | $-18,529 | $-23,341 | $-21,860 | $-18,111 |